Saturday, March 28, 2015
The Weekend Edition is pulled from the daily Stansberry Digest. The Digest comes free with a subscription to any of our premium products.
And the returns in the ProShares Ultra Nasdaq Biotechnology Fund (BIB) – a double-long exchange-traded fund – supports Steve's statement. (Remember, the returns for BIB will be higher than a simple biotech index due to leverage. But the returns for the normal index are still incredible.)
BIB hit a low of $8.48 per share on August 8, 2011. It has soared to more than $160 today – a return of nearly 20 times in less than four years.
Steve has recommended BIB three times in True Wealth Systems since 2012. He recommended shares most recently in October. His subscribers are up 55% on the trade. But if you bought and sold BIB on Steve's recommendations since 2012, you've turned a $100,000 initial investment into nearly $800,000.
The thing is, moves like this in the biotech market aren't unusual...
In the November 25 DailyWealth, Steve showed what a bull market in biotech can mean for investors...
Steve updated readers on his biotech thesis in Monday's DailyWealth. Despite the huge gains True Wealth Systems subscribers have made, Steve still isn't ready to sell. He presented the following chart showing that, while biotech stocks aren't cheap today, they're still far from the valuations we've seen at past peaks...
While Steve is investing in the biotech trend through exchange-traded funds like BIB, Stansberry Venture editor Dave Lashmet is looking for tiny, early stage biotech companies that are poised for huge gains.
In particular, Dave has been researching stocks that fight what the World Health Organization has called "one of the three greatest threats to human health" – antibiotic-resistant bacteria (or "superbugs").
More and more bacteria are becoming resistant to antibiotics today because of overuse. According to the U.S. Centers for Disease Control and Prevention, antibiotic resistance is killing 23,000 Americans a year, making it a real health threat.
Just months after Dave started telling subscribers about superbugs, we saw a scare on American soil. We wrote about it in the February 19 Digest...
Dave explained more about superbugs in the December issue of Stansberry Venture...
Because this problem is so serious, Big Pharma has been spending a fortune to buy up small, promising biotech firms that are developing the drugs to fight superbugs.
Today, Dave is calling for another tiny biotech firm to be bought out...
This company is scheduled to announce final Phase 3 clinical trials in the middle of the year... Dave said it could happen in a matter of weeks. He has been tracking its trials and believes the testing is already finished.
The company just has to compile the data and tell the world if its new drug is a success.
Dave is bullish on this company's prospects. He says that, to date, the trials seem to have shown that this drug demonstrates all the government requirements for approval. And if it does get approval, he believes Big Pharma could buy the company in as little as 18 hours after the announcement.
That's why it's so important to get in now... We don't know when this announcement will take place.
You may be skeptical of Dave's ability to call this takeover. But he has already predicted two buyouts in the sector, which is currently in the midst of an acquisition tear.
The potential for this new company's drug is massive... And Big Pharma won't be able to resist its ability to help fight superbugs.
Plus, Dave's track record since we unveiled Stansberry Venture has been outstanding. He has recommended three companies since November (not including his latest). We can't share the names, per his request. But you can see the gains below (as of March 23):
If you'd like to learn more about Stansberry Venture – our most exclusive service – Dave has put together a presentation telling you a little bit more... and sharing more details about the opportunity he sees right now.
Date Range:3/19/2015 to 3/26/2015
Date Range:3/19/2015 to 3/26/2015